KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Cash from Financing Activities (2016 - 2023)

Historic Cash from Financing Activities for TherapeuticsMD (TXMD) over the last 13 years, with Q4 2023 value amounting to $2.0 million.

  • TherapeuticsMD's Cash from Financing Activities rose 10178.84% to $2.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$108.2 million, marking a year-over-year increase of 5399.56%. This contributed to the annual value of $3.2 million for FY2023, which is 10133.97% up from last year.
  • TherapeuticsMD's Cash from Financing Activities amounted to $2.0 million in Q4 2023, which was up 10178.84% from -$1000.0 recorded in Q3 2023.
  • TherapeuticsMD's Cash from Financing Activities' 5-year high stood at $111.7 million during Q2 2019, with a 5-year trough of -$120.0 million in Q2 2022.
  • Over the past 5 years, TherapeuticsMD's median Cash from Financing Activities value was $890500.0 (recorded in 2021), while the average stood at $9.2 million.
  • Per our database at Business Quant, TherapeuticsMD's Cash from Financing Activities skyrocketed by 4866981.63% in 2020 and then plummeted by 2813738.32% in 2022.
  • Over the past 5 years, TherapeuticsMD's Cash from Financing Activities (Quarter) stood at $77.0 million in 2019, then tumbled by 58.84% to $31.7 million in 2020, then plummeted by 95.73% to $1.4 million in 2021, then crashed by 8373.84% to -$111.9 million in 2022, then surged by 101.79% to $2.0 million in 2023.
  • Its Cash from Financing Activities stands at $2.0 million for Q4 2023, versus -$1000.0 for Q3 2023 and -$111.9 million for Q4 2022.